# Otsuka Beijing Research Institute clinical trials: 36 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials with Otsuka Beijing Research Institute as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Otsuka Beijing Research Institute: 36 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/otsuka-beijing-research-institute

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 10, 2025 | NCT07166887 | Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male | Otsuka Beijing Research Institute | Phase 1 | Completed | Healthy Subjects | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166887) |
| September 10, 2025 | NCT07166796 | a Phase I PK Study in Healthy Male Subjects. 2 Groups of Healthy Male Subjects | Otsuka Beijing Research Institute | Phase 1 | Completed | Health Subjects | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166796) |
| September 10, 2025 | NCT07166783 | Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol | Otsuka Beijing Research Institute | Phase 1 | Completed | Health Subjects | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166783) |
| August 5, 2025 | NCT07105124 | Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject | Otsuka Beijing Research Institute | Phase 1 | Completed | Healthy Subjects (HS) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105124) |
| October 19, 2023 | NCT06091267 | PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes | Otsuka Beijing Research Institute | Phase 1/2 | Active not recruiting | Myelodysplastic Syndromes | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06091267) |
| June 28, 2023 | NCT05923892 | Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type | Otsuka Beijing Research Institute | Phase 2 | Completed | Irritable Bowel Syndrome of Diarrhea Type (IBS-D) | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05923892) |
| December 28, 2022 | NCT05667623 | To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD | Otsuka Beijing Research Institute | Phase 3 | Completed | Atopic Dermatitis (AD) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05667623) |
| December 14, 2022 | NCT05650320 | To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD | Otsuka Beijing Research Institute | Phase 3 | Completed | Atopic Dermatitis (AD) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05650320) |
| October 17, 2022 | NCT05583474 | OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects | Otsuka Beijing Research Institute | Phase 3 | Completed | Open Angle Glaucoma or Ocular Hypertension | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05583474) |
| June 30, 2022 | NCT05439148 | OPC-61815 in Healthy Chinese Male Subjects | Otsuka Beijing Research Institute | Phase 1 | Completed | Healthy Adult Male | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05439148) |
| January 18, 2020 | NCT04233346 | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | Otsuka Beijing Research Institute | Phase 2 | Completed | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04233346) |
| March 14, 2019 | NCT03874494 | Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia | Otsuka Beijing Research Institute | Phase 3 | Completed | Schizophrenia | 371 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03874494) |
| November 7, 2018 | NCT03734354 | The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects | Otsuka Beijing Research Institute | Phase 1 | Completed | Health | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03734354) |
| November 7, 2018 | NCT03734302 | The Pharmacokinetics, and Safety of Brexpiprazole Tablets in Chinese Healthy Subjects | Otsuka Beijing Research Institute | Phase 1 | Completed | Healthy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03734302) |
| April 4, 2018 | NCT03487783 | Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome | Otsuka Beijing Research Institute | Phase 3 | Completed | Tourette Syndrome | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03487783) |
| April 4, 2018 | NCT03487770 | Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder | Otsuka Beijing Research Institute | Phase 3 | Completed | Autistic Disorder | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03487770) |
| April 3, 2018 | NCT03487198 | The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder | Otsuka Beijing Research Institute | Phase 3 | Terminated | Major Depressive Disorder | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03487198) |
| September 19, 2017 | NCT03287505 | Aripiprazole IM Depot for Chinese Patients With Schizophrenia | Otsuka Beijing Research Institute | Phase 1 | Completed | Schizophrenia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03287505) |
| September 18, 2017 | NCT03285503 | PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia | Otsuka Beijing Research Institute | Phase 1 | Completed | Schizophrenia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03285503) |
| June 1, 2017 | NCT03172871 | Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia | Otsuka Beijing Research Institute | Phase 3 | Completed | Schizophrenia | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03172871) |
| July 22, 2014 | NCT02196805 | A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in... | Otsuka Beijing Research Institute | Not applicable | Completed | Chinese Healthy Volunteers | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02196805) |
| March 28, 2014 | NCT02098460 | To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis... | Otsuka Beijing Research Institute | Phase 4 | Completed | Severe Hypercholesterolemia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02098460) |
| July 26, 2012 | NCT01651156 | Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema | Otsuka Beijing Research Institute | Phase 3 | Completed | Cardiac Edema | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01651156) |
| May 3, 2012 | NCT01590901 | Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects | Otsuka Beijing Research Institute | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01590901) |
| May 24, 2011 | NCT01359462 | Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis | Otsuka Beijing Research Institute | Phase 1 | Completed | Hepatic Cirrhosis, Ascites | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01359462) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 3 | 12 |
| Phase 4 | 4 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 34 |
| Terminated | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 5 |
| Ascites | 3 |
| Liver Cirrhosis | 3 |
| Dermatitis, Atopic | 2 |
| Depressive Disorder, Major | 1 |
| Cerebral Infarction | 1 |
| Stroke | 1 |
| Hyponatremia | 1 |
| Myelodysplastic Syndromes | 1 |
| Hyperlipidemias | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Diabetic Nephropathies | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Multiple Myeloma | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Arteriosclerosis Obliterans | 1 |
| Tourette Syndrome | 1 |
| Glaucoma, Open-Angle | 1 |
| Ocular Hypertension | 1 |
| Autistic Disorder | 1 |
| Hypercholesterolemia | 1 |
| Edema, Cardiac | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Research institutes in the United States](https://specstream.ai/data/businesses/research-institutes/united-states)
- [Insurance agencies in the United States](https://specstream.ai/data/businesses/insurance-agencies/united-states)
- [IP and internet law firms in the United States](https://specstream.ai/data/businesses/ip-and-internet-law-firms/united-states)
- [IT service companies in the United States](https://specstream.ai/data/businesses/it-service-companies/united-states)
- [Kitchen remodelers in the United States](https://specstream.ai/data/businesses/kitchen-remodelers/united-states)
- [Landscaping companies in the United States](https://specstream.ai/data/businesses/landscaping-companies/united-states)
